| Literature DB >> 25477991 |
Abstract
Introduction. Qigong is currently considered as meditative movement, mindful exercise, or complementary exercise and is being explored for relief of symptoms in fibromyalgia. Aim. This narrative review summarizes randomized controlled trials, as well as additional studies, of qigong published to the end of 2013 and discusses relevant methodological issues. Results. Controlled trials indicate regular qigong practice (daily, 6-8 weeks) produces improvements in core domains for fibromyalgia (pain, sleep, impact, and physical and mental function) that are maintained at 4-6 months compared to wait-list subjects or baselines. Comparisons with active controls show little difference, but compared to baseline there are significant and comparable effects in both groups. Open-label studies provide information that supports benefit but remain exploratory. An extension trial and case studies involving extended practice (daily, 6-12 months) indicate marked benefits but are limited by the number of participants. Benefit appears to be related to amount of practice. Conclusions. There is considerable potential for qigong to be a useful complementary practice for the management of fibromyalgia. However, there are unique methodological challenges, and exploration of its clinical potential will need to focus on pragmatic issues and consider a spectrum of trial designs. Mechanistic considerations need to consider both system-wide and more specific effects.Entities:
Year: 2014 PMID: 25477991 PMCID: PMC4247977 DOI: 10.1155/2014/379715
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Summary of randomized controlled trials (RCTs) of qigong for fibromyalgia. Control groups include passive (normal activities, wait-list) and active groups (education, aerobic exercise, sham exercise, and other interventions).
| Study | Intervention, duration, measures | Outcomes | ||||
|---|---|---|---|---|---|---|
| Between group comparisons, except where indicated | ||||||
|
(1) Astin et al. 2003 [ | Intervention: QG (Dance of Phoenix), |
|
| |||
| FIQ | NS | NS | ||||
| Total myalgic score | NS | NS | ||||
| SF-36 pain | NS | NS | ||||
| 6 min walk test | NS | NS | ||||
| Depression (BDI) | NS | NS | ||||
| Note: (1) Due to high attrition, only those completing the entire protocol were analysed. (2) Within-group comparisons at 8 wks and 4 and 6 mos indicate that both groups had significant improvements over time in FIQ, total myalgic score, SF-36 pain, and depression; effects were manifest at 8 wks and maintained to 24 wks. | ||||||
|
| ||||||
|
(2) Mannerkorpi and Arndow 2004 [ | Intervention: QG (style not reported), body awareness (BA) therapy; |
| ||||
| BARS |
| |||||
| FIQ | NS | |||||
| Handgrip test | NS | |||||
| Chair test | NS | |||||
| Note: (1) Due to attrition, only 12 + 10 participated in post-test outcomes. (2) Within-group BARS analysis indicated significant changes in treatment group but not control group; within-group FIQ total score analysis indicates significant changes in control group but not treatment group. | ||||||
|
| ||||||
| (3) Stephens et al. 2008 [ | Intervention: QG exercises (18 postures, style not reported) versus aerobic exercise; 30 min of practice in 1 group session + 2 home sessions each week |
| ||||
|
|
|
|
| |||
|
| ||||||
|
(4) Haak and Scott 2008 [ | Intervention: QG (He Hua Qigong) 11.5 hrs instructions/practice over 7 wks; encouraged to practice at home (2 × 20 min/day); subjects also had 2 external QG sessions |
|
| |||
| Pain (VNS) |
|
|
| |||
| Intensity | 0.63 | <0.001 | <0.05 | |||
| Inconvenience | 0.73 | <0.01 | <0.05 | |||
| Control of pain | 0.61 | <0.01 | NS | |||
| Sleep (VNS) | ||||||
| Restoration | 0.44 | <0.001 | <0.01 | |||
| Quality | NS | <0.001 | <0.01 | |||
| Psychological | ||||||
| STAI (anxiety) | 0.66 | <0.05 | <0.01 | |||
| BDI (depression) | 0.69 | <0.01 | <0.001 | |||
| QOL total | 0.55 | <0.001 | <0.01 | |||
| QOL psychological | 0.52 | <0.001 | <0.001 | |||
| QOL physical | NS | <0.01 | <0.001 | |||
| Note: (1) Many between-group effect sizes following the intervention are in the moderate-to-large range (0.5–0.8). (2) Combination group data reports postintervention and longer-term outcomes for N = 56 subjects. (3) While benefits are sustained over time, SMDs at follow-up compared to BL range from 0.2 to 0.7. | ||||||
|
| ||||||
|
(5) Liu et al. 2012 [ | Intervention: QG (Liu Zi Jue Qigong, “Six Healing Sounds”), 2 training sessions, weekly group sessions (45–60 min), daily home-practice (2 × 15–20 min, morning and evening). Sham had the same movements, but no meditation or healing sounds. |
|
| |||
| SF-MPQ (pain) | ↓44% ( | ↓10% (NS) | ||||
| MFI (fatigue) | ↓25% ( | ↓6% (NS) | ||||
| PSQI (sleep) | ↓37% ( | ↓10% (NS) | ||||
| FIQ (impact) | ↓44% ( | ↓12% (NS) | ||||
|
Note: (1) Between-group Cohen's | ||||||
|
| Note: Participants asked to keep diary of home-practice. Compliance was moderately high (75–85% daily, 77–79% group sessions). |
|
|
|
| |
|
| ||||||
|
(6) Lynch et al. 2012 [ | Intervention: QG (Chaoyi Fanhuan Qigong, CFQ); 3 half-day training sessions (4 hrs each); weekly review/practice session (60 min); daily home-practice (45 mins) |
|
|
| ||
| NRS (pain) | imm | <0.001 | 0.01 | <0.05 | ||
| del | 0.01 | 0.005 | <0.05 | |||
| FIQ (impact) | imm | <0.001 | 0.003 | 0.007 | ||
| del | <0.001 | 0.01 | 0.05 | |||
| PSQI (sleep) | imm | 0.001 | <0.001 | 0.003 | ||
| del | 0.009 | NS* | NS* | |||
| SF-36 physical | imm | <0.001 | <0.001 | 0.004 | ||
| del | <0.01 | <0.001 | 0.01 | |||
| SF-36 mental | imm | 0.002 | NS | NS | ||
| del | 0.004 | NS | NS* | |||
|
Note: (1) Individual QG groups (imm, del) showed good reproducibility when compared to wait-list. (2)*P < 0.01 in combination group analysis. (3) Combination group data reports post-intervention and follow-up data for the N = 73 who completed the trial to 6 months; it includes participants from both the immediate and the delayed intervention groups. (4) Combination group SMD values compared to wait-list are 0.81 (0.67, 0.56 at F-UP) for pain, 1.16 (0.63, 0.57 at F-UP) for impact, 0.71 (0.60, 0.52 at F-UP) for sleep, 0.80 (0.72, 0.56 at F-UP) for physical function, and 0.79 (0.23, 0.49 at F-UP) for mental function. (5) In the | ||||||
|
(7) Maddali Bongi et al. 2012 [ | Group1: RM + QG |
| ||||
|
|
|
|
| |||
| FIQ | <0.001 | <0.001 | <0.001 | |||
| HAQ | <0.001 | <0.001 | <0.001 | |||
| NRS (pain) | <0.001 | <0.001 | <0.001 | |||
| RPS (pain) | <0.001 | <0.001 | <0.001 | |||
| NRS (sleep) | NS | NS | NS | |||
| HADS-A | <0.001 | <0.001 | <0.001 | |||
| HADS-D | NS | <0.001 | <0.001 | |||
| SF-36 PCS | <0.001 | <0.001 | <0.001 | |||
| SF-36 MCS | NS | NS | NS | |||
|
|
|
|
| |||
| FIQ | <0.05 | <0.001 | <0.05 | |||
| HAQ | <0.001 | <0.001 | <0.001 | |||
| NRS (pain) | <0.001 | <0.001 | <0.001 | |||
| RPS (pain) | <0.001 | <0.001 | <0.001 | |||
| NRS (sleep) | NS | <0.05 | NS | |||
| HADS-A | <0.001 | <0.001 | <0.001 | |||
| HADS-D | <0.001 | <0.001 | <0.001 | |||
| SF-36 PCS | <0.05 | <0.001 | <0.001 | |||
| SF-36 MCS | NS | NS | NS | |||
| Note: (1) QG and RM produce comparable benefits compared to BL over a range of outcomes when applied as an initial intervention. When they are implemented as a sequential intervention, most outcomes are not different from the end of the first intervention. (2) Effects are generally maintained in the follow-up interval to 6 mos. (3) SMD values for FIQ, HAQ, RPS, HADS-A, HADS-D, and SF-36 PCS generally range from 0.7 to 1.5 in both groups (8 wks–6 mos). | ||||||
BA, body awareness; BARS, body awareness rating scale; BDI, Beck Depression Inventory; BL, baseline; CG, control or comparison group; del, delayed intervention group; FIQ, fibromyalgia impact questionnaire; FM, fibromyalgia; F-UP, follow-up; HADS, Hospital Anxiety and Depression Scale (A-anxiety, D-depression); HAQ, health assessment questionnaire; hrs, hours; imm, immediate intervention group; MFI, Multidimensional Fatigue Inventory; MM, mindfulness meditation; mos, months; NRS, numerical rating scale; NS, nonsignificant (P > 0.05); PSQI, Pittsburgh Sleep Quality Index; QG, qigong group; QOL, quality of life; RM, Rességuier method; RPS Regional Pain Scale; SF-36, short form-36 (MCS mental component summary, PCS physical component summary); SF-MPQ, short form- McGill pain questionnaire; SMD, standard mean difference; STAI, State Anxiety Inventory; T1, treatment 1; T2, treatment 2; VNS, visual numerical scale; wks, weeks; yrs, years.
Summary of other studies of qigong for fibromyalgia.
| Study | Intervention, duration | Outcomes |
|---|---|---|
| (1) Creamer et al. 2000 [ | Attendance at 8 weekly sessions (2.5 hrs each), with educational and cognitive/behavioural component (30 min), relaxation/meditation (60 min), qigong (60 min, form not specified) | Significant ( |
|
| ||
| (2) Chen et al. 2006 [ | External qigong therapy applied for 5–7 sessions (45 mins) over 3 wks; monthly maintenance session | Significant improvements in impact (FIQ), depression (BDI), pain (MPQ, VAS), and anxiety following the intervention. Changes were maintained at 1 and 3 months, although there was some rebound. Pre-post SMD values were 1.1–1.9 at 3 wks, 0.7–1.7 at the 1 mo F-UP, and 0.8–1.4 at the 3 mos F-UP. Sleep (PSQI) scores were not significantly improved. |
|
| ||
| (3) Lynch et al. 2009 [ | Two half-day (4 hrs) qigong training sessions (level 1 CFQ), weekly review/practice session (90 min), daily home-practice (45 min). | Significant improvements in pain (NRS), impact (FIQ), and physical function (SF-36), either following treatment or at F-UP. |
|
| ||
| (4) Sawynok et al. 2013 [ | Extensive qigong practice (levels 1 and 2 CFQ). Both attended an initial 8-day workshop in 2008 and subsequently practiced daily for an extended interval (≥1 hr for 6 mos); one undertook repeat training/practice sessions. In 2009 and 2010, both attended additional workshops (8–10 days) and continued extensive daily practice (1.5–3 hrs/day) at times. |
|
|
| ||
| (5) Sawynok et al. 2013 [ | Two half-day (4 hrs) qigong sessions (level 2 CFQ), weekly review/practice session (60 min), daily home-practice (60 min) for 8 wks. Home-practice mix of levels 1 and 2 CFQ. |
|
|
| ||
| (6)Sawynok and Lynch 2014 [ | No additional qigong practice. Retrospective analysis of initial 6- month experience with practice of level 1 CFQ. Post hoc consideration clustered around (a) motivation/perseverance and (b) amount of practice. |
|
BDI, Beck Depression Inventory; BL, baseline; CFQ, Chaoyi Fanhuan Qigong; FIQ, fibromyalgia impact questionnaire; FM, fibromyalgia; F-UP, follow-up; hrs, hours; mo, month; min, minute; MPQ McGill pain questionnaire; NRS, Numerical Rating Scale; PSQI, Pittsburgh Sleep Quality Index; RCT, randomized controlled trial; SF-36, Short Form-36; SMD, standard mean difference; VAS, Visual Analog Scale; wk(s), week(s); yrs, years.
Methodological issues relating to qigong studies for fibromyalgia.
| Issue | Comments |
|---|---|
| (1) Plurality of forms | (i) Qigong has a long history and is part of traditional Chinese medicine; many forms have evolved; different contexts (martial arts, health benefits, and spiritual development) emphasize different elements. |
|
| |
| (2) Components of practice | (i) Qigong consists of movement, breath instruction, and mental/mind components. |
|
| |
| (3) Amount of practice | (i) Internal qigong involves self-practice, while external qigong involves highly skilled practitioners; most FM studies use self-practice. |
|
| |
| (4) Effectiveness of practice | Not all practice time is equally effective. Movements can take time to learn, and nuances of execution can matter. With mental instructions, it can be a challenge to determine parameters that reflect effective engagement. |
|
| |
| (5) Control/comparator group | (i) Some trials strive to isolate an active component of an intervention, to delineate “specific” from “nonspecific” factors. |
|
| |
| (6) Multiple trial designs | (i) RCTs involve controlled settings, defined inclusion-exclusion criteria, predetermined primary and secondary outcomes, and comparison to placebo or comparator groups, and provide information that is relevant to the regulatory approval process. |
|
| |
| (7) Participants, subgroups | (i) FM involves widespread pain and multiple somatic symptoms (disturbances in sleep, mood, and other functions) and can differ in terms of chronicity (duration) and additional symptomology (part of FM or comorbidity). |
|
| |
| (8) Outcomes | (i) FM outcomes can be considered in the context of chronic pain or as condition-specific outcomes. |